Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.

Abstract

Therapeutic immune checkpoint blockade for metastatic melanoma has been associated with vitiligo, pruritus and morbilliform eruptions. Reports of other autoimmune skin disease in this setting are rare. We sought to expand the spectrum of cutaneous immune-mediated effects related to immune checkpoint inhibitor therapy. In this report, we describe two unusual cutaneous reactions related to checkpoint inhibitor therapy, namely bullous pemphigoid (BP) and dermatitis herpetiformis. The development of BP and dermatitis herpetiformis in the context of checkpoint inhibitor therapy is consistent with previous investigations supporting the importance of effector and regulatory T cells in the pathogenesis of these diseases.

• Authors: Mark C Mochel, Michael E Ming, Sotonye Imadojemu, Tara C Gangadhar, Lynn M Schuchter, Rosalie Elenitsas, Aimee S Payne, Emily Y Chu
• Journal: Journal of cutaneous pathology (J Cutan Pathol) Vol. 43 Issue 9 Pg. 787-91 (Sep 2016) ISSN: 1600-0560 [Electronic] United States
• PMID: 27161449 (Publication Type: Case Reports)
• Copyright: © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Ipilimumab
• pembrolizumab

Topics

• Adult
• Antibodies, Monoclonal (adverse effects)
• Antibodies, Monoclonal, Humanized (adverse effects)
• Antineoplastic Agents (adverse effects)
• Autoimmune Diseases (chemically induced, pathology)
• Dermatitis Herpetiformis (chemically induced, pathology)
• Drug Eruptions (etiology, pathology)
• Female
• Humans
• Ipilimumab
• Male
• Melanoma (drug therapy, secondary)
• Middle Aged
• Pemphigoid, Bullous (chemically induced, pathology)
• Skin Neoplasms (drug therapy, secondary)